Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 12, 2009

Premium

Gary Gilliland has taken on two posts at Merck, including vice president of Merck Research Laboratories and franchise head of oncology.

Gilliland is a Harvard Medical School professor and a Howard Hughes Medical Institute investigator. He is also director for the Leukemia Program at the Dana Farber/Harvard Medical Cancer Center and director of the Cancer Stem Cell Program at the Harvard Stem Cell Institute.

He will replace Stephen Friend, who plans to leave the company to pursue an effort to build open access integrative bionetworks, or complex databases, around the world in order to accelerate disease studies.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more